Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras
Modern Hodgkin lymphoma treatments substantially reduce second-cancer risk, though long-term breast and lung surveillance remains important for survivors.
A national cohort followed 7,428 female Hodgkin lymphoma survivors across six decades of treatment. Modern care reduced solid second cancers, yet lifelong breast and lung cancer surveillance remains important because excess risk persisted beyond 50 years.
What the study was
- Study design
- Population-based national cohort with registry linkage
- Population
- Women diagnosed with Hodgkin lymphoma before age 36 in England and Wales
- Sample size
- 7,428
- Category
- Public Health
- Maturity
- Validated
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Why it surfaced
Long follow-up and national registry linkage make the survivorship risk estimates clinically important, though the analysis remains observational.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.